News

Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s portfolio of microarray-based nuclear hormone receptor

In this second study, administration of A-002 lowered both secretory phospholipase A2 (sPLA2) and low density lipoprotein cholesterol (LDL-C) levels confirming the positive effects of A-002 treatment seen

In the independently conducted, large-scale, randomized, single-blind study by J-WIND in 603 patients, carperitide, when administered to acute myocardial infarction (AMI) patients after reperfusion treatment, was associated with

The objective of the Phase II trial is to evaluate the safety and anticancer activity of alvespimycin as a single agent in patients who have not previously received

The European patent covers the composition of matter of Provenge (sipuleucel-T) as well as the company’s other active cellular immunotherapy (ACI) product candidates, such as Neuvenge (lapuleucel-T). The

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with intravenous (IV) vancomycin

bioMerieux will become Quidel’s primary distributor for its QuickVue rapid diagnostic tests outside the US and the two companies intend to co-develop new rapid tests using Quidel’s rapid

The results of this study indicate that no chromosomal aberrations were induced in peripheral blood lymphocytes when Treximet was administered to volunteers for seven days. The submission of

Tysabri will be available for patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease (CD) therapies and